Evidence map›Paper›PMID 24566273›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2014

Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids.

Jia Fan, Shiwen Niu, Ailian Dong, Jian Shi, Hung-Jen Wu, Daniel H Fine, Yaping Tian, Chunxi Zhou, Xuewu Liu, Tong Sun and 5 more

Abstract read
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jia FanChinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China; Department of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA.
Shiwen NiuChinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China; College of Pharmaceutical Science, Jilin University, Changchun, China.
Ailian DongChinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China; The First Affiliated Hospital of Jilin University, Changchun, China.
Jian ShiChinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China.
Hung-Jen WuDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA.
Daniel H FineDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA.
Yaping TianDepartment of Clinical Biochemistry, Chinese PLA General Hospital, Beijing, China.
Chunxi ZhouBruker Daltonics Inc. Beijing Office, Beijing, China.
Xuewu LiuDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA.
Tong SunDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA.
Gregory J AndersonQueensland Institute of Medical Research, Royal Brisbane Hospital, Brisbane, Queensland, Australia.
Mauro FerrariDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA; Weill Cornell Medical College of Cornell University, New York City, NY, USA.
Guangjun NieChinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China.
Ye HuDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX, USA; Weill Cornell Medical College of Cornell University, New York City, NY, USA. Electronic address: yhu@HoustonMethodist.org.
Yuliang ZhaoChinese Academy of Science Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China. Electronic address: zhaoyuliang@ihep.ac.cn.

Funding

Texas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4M
NCI NIH HHS U54 CA151668NCI NIH HHS U54CA151668
6 · The paper itself

Abstract

Endogenous peptides that represent biological and pathological information of disease have attracted interest for diagnosis. However, the extraction of those low abundance peptides is still a challenge because of the complexity of human bodily fluids (HBF). Hepcidin, a peptide hormone, has been recognized as a biomarker for iron-related diseases. There is no rapid and reliable way to enrich them from HBF. Here we describe a peptide extraction approach based on nanoporous silica thin films to successfully detect hepcidin from HBF. Cooperative functions of nanopore to biomolecule, including capillary adsorption, size-exclusion and electrostatic interaction, were systematically investigated to immobilize the target peptide. To promote this new approach to clinical practices, we further applied it to successfully assay the hepcidin levels in HBF provided by healthy volunteers and patients suffering from inflammation. Our finding provides a high-throughput, rapid, label-free and cost-effective detection method for capturing and quantifying low abundance peptides from HBF. FROM THE CLINICAL EDITOR: Diagnosing diseases with low concentration peptide biomarkers remains challenging. This team of authors describes a peptide extraction approach based on nanoporous silica thin films to successfully detect low concentrations of hepcidin from human body fluids collected from 119 healthy volunteers and 19 inflammation patients.

Indexed as

NanoporesBiomarkersBody FluidsHepcidinsHumansMembranes, ArtificialPeptidesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationBiomarkersHepcidinsMembranes, ArtificialPeptidesBiomarker discoveryHepcidinMALDI-TOF MSNanoporous silica filmPeptide

Identifiers

PMID24566273
PMCPMC4077980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.